Literature DB >> 22705885

The endocytic adaptor protein Disabled-2 is required for cellular uptake of fibrinogen.

Wei-Shan Hung1, Chien-Ling Huang, Jui-Ting Fan, Ding-Yuan Huang, Chun-Fung Yeh, Ju-Chien Cheng, Ching-Ping Tseng.   

Abstract

Endocytosis is pivotal for uptake of fibrinogen from plasma into megakaryocytes and platelet α-granules. Due to the complex adaptor and cargo contents in endocytic vehicles, the underlying mechanism of fibrinogen uptake is not yet completely elucidated. In this study, we investigated whether the endocytic adaptor protein Disabled-2 (DAB2) mediates fibrinogen uptake in an adaptor-specific manner. By employing primary megakaryocytes and megakaryocytic differentiating human leukemic K562 cells as the study models, we found that fibrinogen uptake is associated with the expression of integrin αIIbβ3 and DAB2 and is mediated through clathrin-dependent manner. Accordingly, constitutive and inducible knockdown of DAB2 by small interfering RNA reduced fibrinogen uptake for 53.2 ± 9.8% and 59.0 ± 10.7%, respectively. Culturing the cells in hypertonic solution or in the presence of clathrin inhibitor chlorpromazine abrogated clathrin-dependent endocytosis and diminished the uptake of fibrinogen. Consistent with these findings, 72.2 ± 0.2% of cellular DAB2 was colocalized with clathrin, whereas 56.4±4.1% and 54.6 ± 2.0% of the internalized fibrinogen were colocalized with clathrin and DAB2, respectively. To delineate whether DAB2 mediates fibrinogen uptake in an adaptor-specific manner, K562 stable cell lines with knockdown of the adaptor protein-2 (AP-2) or double knockdown of AP-2/DAB2 were established. The AP-2 knockdown cells elicited normal fibrinogen uptake activity but the uptake of collagen was diminished. In addition, collagen uptake was further reduced in DAB2/AP-2 knockdown cells. These findings thereby define an adaptor-specific mechanism in the control of fibrinogen uptake and implicate that DAB2 is the key adaptor in the clathrin-associated endocytic complexes to mediate fibrinogen internalization.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22705885     DOI: 10.1016/j.bbamcr.2012.06.008

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Disabled-2 is required for efficient hemostasis and platelet activation by thrombin in mice.

Authors:  Hui-Ju Tsai; Chien-Ling Huang; Yao-Wen Chang; Ding-Yuan Huang; Chung-Ching Lin; Jonathan A Cooper; Ju-Chien Cheng; Ching-Ping Tseng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-09-11       Impact factor: 8.311

Review 2.  The adaptor protein Disabled-2: new insights into platelet biology and integrin signaling.

Authors:  Hui-Ju Tsai; Ching-Ping Tseng
Journal:  Thromb J       Date:  2016-10-04

3.  Disabled-2 is a negative immune regulator of lipopolysaccharide-stimulated Toll-like receptor 4 internalization and signaling.

Authors:  Wei-Shan Hung; Pin Ling; Ju-Chien Cheng; Shy-Shin Chang; Ching-Ping Tseng
Journal:  Sci Rep       Date:  2016-10-17       Impact factor: 4.379

Review 4.  The life cycle of platelet granules.

Authors:  Anish Sharda; Robert Flaumenhaft
Journal:  F1000Res       Date:  2018-02-28

5.  Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombasthenia.

Authors:  Loredana Bury; Emanuela Falcinelli; Davide Chiasserini; Timothy A Springer; Joseph E Italiano; Paolo Gresele
Journal:  Haematologica       Date:  2015-10-09       Impact factor: 9.941

Review 6.  Impacts of Cancer on Platelet Production, Activation and Education and Mechanisms of Cancer-Associated Thrombosis.

Authors:  Léa Plantureux; Diane Mège; Lydie Crescence; Françoise Dignat-George; Christophe Dubois; Laurence Panicot-Dubois
Journal:  Cancers (Basel)       Date:  2018-11-14       Impact factor: 6.639

Review 7.  Endocytic Adaptor Proteins in Health and Disease: Lessons from Model Organisms and Human Mutations.

Authors:  Domenico Azarnia Tehran; Tania López-Hernández; Tanja Maritzen
Journal:  Cells       Date:  2019-10-29       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.